HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

AVNS

Avanos Medical, Inc. (NYSE)

Healthcare — Medical Devices

Avanos Medical, Inc., a medical technology company, provides medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides non-opioid pain solutions, including surgical pain and recovery products, which comprise ON-Q and ambIT surgical pain pump, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which provide minimally invasive pain-relieving therapies, such as COOLIEF chronic pain products; and Trident and Esentec RFA radiofrequency ablation products to treat chronic pain conditions. The company markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. Avanos Medical, Inc. was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. The company was incorporated in 2014 and is headquartered in Alpharetta, Georgia.

None
$24.88
$-0.25 (-0.20%)
Sign in to add AVNS to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$1.17B
P/E Ratio (TTM)-
Forward P/E19.90
EPS (TTM)$-1.60
Dividend Yield-
Profit Margin-10.39%
Revenue Growth8.80%
ROE-9.18%
Debt/Equity17.70
Recommendation None
Analyst Target-
Analysts-
Indexes NYSE

Technical Indicators

RSI (14)34.7
Beta1.58
SMA 20-
SMA 40-
52-Week High$25.49
52-Week Low$9.30
50-Day Avg$24.81
200-Day Avg$15.74
Avg Volume$1.59M
Volume310.0K

Performance Analysis

NEUTRAL

AVNS presents a mixed picture with both positive and negative indicators.

- Trading near its 52-week high ($25.49), which may indicate limited upside.
~ RSI at 34.7 is in neutral territory.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
~ Modest revenue growth of 8.8% year-over-year.
- Operating at a loss with -10.4% margin.
~ Wall Street consensus is "none".

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jun 30, 2026 21:08 UTC

Back to Screener Export Report